Stifel Nicolaus Cuts Pulmonx (NASDAQ:LUNG) Price Target to $16.00

Pulmonx (NASDAQ:LUNG) had its price target reduced by Stifel Nicolaus from $17.00 to $16.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also issued reports on LUNG. Canaccord Genuity Group upped their target price on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company reduced their price objective on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Pulmonx Stock Up 0.3 %

Shares of NASDAQ LUNG opened at $6.27 on Thursday. The firm has a market cap of $245.47 million, a P/E ratio of -4.27 and a beta of 0.68. The firm’s 50 day moving average price is $7.24 and its 200 day moving average price is $7.25. Pulmonx has a 1 year low of $5.46 and a 1 year high of $14.84. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative return on equity of 51.92% and a negative net margin of 72.01%. The business had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.39 million. During the same quarter in the previous year, the business earned ($0.39) EPS. As a group, sell-side analysts anticipate that Pulmonx will post -1.64 earnings per share for the current year.

Insider Activity

In other news, insider Geoffrey Beran Rose sold 4,586 shares of Pulmonx stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the transaction, the insider now directly owns 295,433 shares of the company’s stock, valued at $1,979,401.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Pulmonx news, insider Geoffrey Beran Rose sold 4,586 shares of Pulmonx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total transaction of $30,726.20. Following the completion of the sale, the insider now owns 295,433 shares of the company’s stock, valued at $1,979,401.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel David Aaron Lehman sold 5,765 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $6.69, for a total value of $38,567.85. Following the sale, the general counsel now directly owns 203,348 shares of the company’s stock, valued at $1,360,398.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,351 shares of company stock worth $361,494. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LUNG. Price T Rowe Associates Inc. MD grew its holdings in Pulmonx by 4.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock valued at $332,000 after purchasing an additional 1,633 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after buying an additional 1,800 shares during the period. nVerses Capital LLC acquired a new position in Pulmonx in the 3rd quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Pulmonx in the 2nd quarter valued at $37,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after acquiring an additional 7,316 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.